Bionano Genomics, Inc. (BNGO) stock
BNGONasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 12/3085% below fair value
$0.82−0.06 (-7.10%)
Close on Nov 20, 2026Market cap $9.68MP/E –Yield –
Bionano Genomics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Bionano Genomics's free cash flow for the twelve months ending Sep 30, 2021 was -$58.75M. For fiscal 2020 it was -$38.31M.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | -$38.31M | – |
| FY2019 | Dec 31, 2019 | -$29.59M | – |
| FY2018 | Dec 31, 2018 | -$20.28M | – |
| FY2017 | Dec 31, 2017 | -$21.84M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2021 | Sep 30, 2021 | -$20.25M | – |
| Q2 FY2021 | Jun 30, 2021 | -$12.47M | – |
| Q1 FY2021 | Mar 31, 2021 | -$13.93M | – |
| Q4 FY2020 | Dec 31, 2020 | -$12.10M | – |
| Q3 FY2020 | Sep 30, 2020 | -$10.96M | – |
| Q2 FY2020 | Jun 30, 2020 | -$7.22M | – |
| Q1 FY2020 | Mar 31, 2020 | -$8.03M | – |
| Q4 FY2019 | Dec 31, 2019 | -$9.40M | – |
| Q3 FY2019 | Sep 30, 2019 | -$7.29M | – |
| Q2 FY2019 | Jun 30, 2019 | -$6.35M | – |
| Q1 FY2019 | Mar 31, 2019 | -$6.55M | – |
| Q4 FY2018 | Dec 31, 2018 | -$4.10M | – |
| Q3 FY2018 | Sep 30, 2018 | -$6.23M | – |
| Q2 FY2018 | Jun 30, 2018 | -$3.14M | – |
| Q1 FY2018 | Mar 31, 2018 | -$6.80M | – |
| Q4 FY2017 | Dec 31, 2017 | -$3.09M | – |
See a number that looks wrong?